References
- Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132.
- Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003-2005: a population-based study. Int J Cancer. 2015;136:1921–1930.
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249.
- Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364:1708–1717.
- Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238–244.
- Halabi S, Lin CY, Kelly WK, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. JCO. 2014;32:671–677.
- Valderrama A, Tangirala K, Babajanyan S, et al. Treatment, healthcare resource utilization, and costs associated with non-metastatic and metastatic castration-resistant prostate cancer: A claims analysis. J Clin Oncol. 2017;35:e18341.
- Kovačević A, Dragojević-Simić V, Rančić N, et al. End-of-life costs of medical care for advanced stage cancer patients. Vojnosanit Pregl. 2015;72:334–341.
- Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–479.
- Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. JCO. 2009;27:3742–3748.
- Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013;190:429–438.
- https://data.worldbank.org/indicator/FP.CPI.TOTL.ZG?locations=CN
- Huo YY, Dai B, Kong YY, et al. Risk factors associated with overall survival in mCRPC patients receiving docetaxel-based chemotherapy. CJC. 2012;10:779–783.
- Heijnsdijk EA, De Carvalho TM, Auvinen A, et al. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J Natl Cancer Inst. 2014;107(1):366.
- Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242–245.
- He D, Sun Z, Guo J, et al. 813P Real-world use of docetaxel for metastatic castration-resistant prostate cancer in China: Results from a large observational study. Ann Oncol. 2017;28(suppl_5).
- Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. The Lancet. 1995;346:265–269.
- De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.
- Ryan CJ, Smith MR, De Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–148.
- The annual national report of China health development in 2016. http://www.nhfpc.gov.cn/guihuaxxs/s10748/201708/d82fa7141696407abb4ef764f3edf095.shtml
- Dragomir A, Dinea D, Vanhuyse M, et al. Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. BMC Health Serv Res. 2014;14:252.
- Roehrborn CG, Black LK. The economic burden of prostate cancer. BJU Int. 2011;108:806–813.